ceramide

A potent modulator of cell proliferation and differentiation.

C16 dihydro Ceramide (d18:0 16:0) (Cer(d18:0 16:0)) 是合成神经酰胺的前体，诱导核周区域自噬，可用于研究细胞膜的稳定性和神经系统疾病。

C22 Ceramide (d18:1 22:0) (C22 Ceramide) 是一种从海绵Haliclona koremella 中分离出含有山嵛酸的长链神经酰胺，是一种内源性生物活性鞘脂。C22 Ceramide (d18:1 22:0) 可特异性抑制MCSR，降低离体大鼠肝线粒体和脂质体中 C16-神经酰胺通道的形成。

N-Desmethyltamoxifen hydrochloride 是 Tamoxifen 在人体内主要的三苯氧胺代谢物。它是蛋白激酶 C 抑制剂，也是人体 AML 细胞神经酰胺代谢的有效调节因子，可限制神经酰胺糖基化、水解和鞘氨醇磷酸化。

Aureobasidin A 是一种环肽和抗真菌抗生素。它是肌醇磷酸神经酰胺合酶 AUR1 的抑制剂。

ω-azido-C6 Ceramide 能降低膜电位，并对Neisseria 展现抗菌活性，其中对 N. meningitidis MC58 和 N. gonorrhoeae FA1090 的最小抑制浓度（MIC）均为 2 µg mL。

C16 Ceramide (d16:1, C16:0) 是一种具有生物活性的鞘脂，能够在棕榈酰磷脂 (POPC) 双层中诱导富含棕榈酰鞘磷脂结构域的有序相和凝胶相的形成及其热稳定性。此化合物存在于人红细胞鞘磷脂中。

Ceramide 1-phosphate 是一种具有生物活性的脂质，同时也是鞘脂的重要组成部分之一。它在细胞分化、迁移、增殖和死亡等细胞活动中发挥多重作用。

Ceramide 1 A 是一种蜡状脂质化合物，是顶端皮肤层的脂质。它具有特殊的分子结构，因为它含有一种与长链ω-羟基酸相连的亚油酸。

C18 dihydro Ceramide is a bioactive sphingolipid and precursor in the de novo synthesis of C18 ceramide that lacks the 4,5-trans double bond. [1] Increased C18 dihydroceramide lipid levels lead to increased triacylglycerol storage and autophagosome accumulation as well as upregulation of the fibrosis markers α-SMA and FGF2 in Chang and LX-2 liver cells. C18 dihydro Ceramide is elevated in the plasma of pre-diabetics up to 9 years prior to the onset of type 2 diabetes. [2] It is also elevated in the skin of patients with lesional atopic dermatitis.[3]

C18:1 Ceramide (d18:1 18:1(9Z))是一种神经酰胺，C18:1-Ceramide水平在超重和胰岛素抵抗小鼠和牛以及晚期卵巢癌患者血浆和卵巢组织中升高。

C2 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It stimulates cholesterol efflux in CHO cells expressing the human ABCA1 receptor when used at a concentration of 10 μM, however, this efflux is 50% less than that stimulated by C2 ceramide . C2 L-threo Ceramide inhibits IL-4 production by 17% in EL4 T cells stimulated with phorbol 12-myristate 13-acetate when used at a concentration of 10 μM. It also induces cell cycle arrest in the G0 G1 phase and a 7-fold increase in sphingosine accumulation as well as inhibits growth of HL-60 leukemia cells.

BODIPY-C12 Ceramide（B12Cer）是C12鞘氨醇的荧光标记形式，其激发 发射最大值分别为505 540 nm。BODIPY-C12 Ceramide 是一种带有荧光标记的神经酰胺。BODIPY-C12 Ceramide已被用于量化尼曼-匹克病患者血浆中酸性鞘磷脂酶的活性。

Ceramide phosphoethanolamine (CPE) is an analog of sphingomyelin that contains ethanolamine rather than choline as the head group. It is the principal membrane phospholipid in invertebrates such as Drosophila, which lacks sphingomyelin. It is only produced in small amounts in mammalian cells, accounting for approximately 0.02 mol% of total phospholipids in mouse testis and brain. In Drosophila, CPE is biosynthesized by CPE synthase from ceramide and cytidine diphosphate-ethanolamine in the Golgi lumen. In mammals, it is biosynthesized by sphingomyelin synthase 2 (SMS2) in the plasma membrane and by sphingomyelin synthase-related protein (SMSr) in the endoplasmic reticulum (ER). In Drosophila, CPE has a role in glial ensheathment of axons. Disrupting CPE synthesis by depleting SMSr in vitro in mammalian cells leads to an accumulation of ER ceramides, which are then mislocalized to the mitochondria, inducing apoptosis. However, ceramide levels are not altered in transgenic mice lacking SMSr catalytic activity. CPEs (bovine) is a mixture of CPEs with variable N-acyl chain lengths.

C2 Ceramide (d14:1 2:0) is a bioactive sphingolipid. Dietary administration of C2 ceramide (d14:1 2:0) (100 μM) induces lipotoxic cardiomyopathy via increasing diastolic and systolic diameter as well as reducing fractional shortening and the number of normal cardiac contractile events in Drosophila.

C6 L-erythro Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It is metabolized by ceramide glucosyltransferase to form C6 L-erythro glucosylceramide. C6 L-erythro Ceramide is cytotoxic to U937 cells (IC50 = 18 μM).

C6 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides., C6 L-threo Ceramide is cytotoxic to U937 cells in vitro (IC50 = 18 μM). It is metabolically inactive and, unlike C6 L-erythro ceramide , C6 L-threo ceramide cannot be converted to C6 glucosylceramide by ceramide glucosyltransferase. C6 L-threo Ceramide enhances IL-4 production induced by phorbol 12-myristate 13-acetate in EL4 T cells when used at a concentration of 10 μM.

C6 urea ceramide is an inhibitor of neutral ceramidase.1 It increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and in HT-29 colon cancer cells but not in MEFs lacking neutral ceramidase. It inhibits proliferation of, and induces apoptosis and autophagy in HT-29, but not non-cancerous RIE-1, cells when used at concentrations of 5 and 10 μM. C6 urea ceramide decreases total β-catenin, increases phosphorylated β-catenin, and induces colocalization of β-catenin with the 20S proteasome in HT-29 and HCT116, but not RIE-1, cells. It reduces tumor growth and increases C16, C18, C20, and C24 ceramide levels in tumor tissue in an HT-29 mouse xenograft model when administered at doses of 1.25, 2.5, and 5 mg/kg for five days. |1. García-Barros, M., Coant, N., Kawamori, T., et al. Role of neutral ceramidase in colon cancer. FASEB J. 30(12), 4159-4171 (2016).

C8 D-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It is cytotoxic to U937 cells (IC50 = 17 μM) and induces nuclear DNA fragmentation 5- to 6-fold more potently than C8 ceramide . C8 D-threo Ceramide is a substrate for E. coli diacylglycerol kinase. It activates ceramide-activated protein kinase (CAPK) in U937 cells. C8 D-threo Ceramide also enhances V. cholerae cytolysin pore formation in liposome lipid membranes, as measured by calcein release, with a 50% release dose (RD50) value of ~5 μg ml.

C8 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It is cytotoxic to U937 cells (IC50 = 10 μM) and, like C8 D-threo ceramide , induces nuclear DNA fragmentation 5- to 6-fold more potently than C8 L-erythro ceramide . C8 D-threo Ceramide also enhances V. cholerae cytolysin pore formation in liposome lipid membranes, as measured by calcein release, with a 50% release dose (RD50) value of ~30 μg ml.

C12-Ceramide (C12 Ceramide (d18:1 12:0)) 是一种存在于先兆子痫妇女所生婴儿围绕脐带血管的保护膜的神经酰胺，是 C12 鞘磷脂被酸性鞘磷脂酶（ASM）水解后形成的，可用于评估 A 型或 B 型尼曼-皮克病患者血浆中的 ASM 活性水平。

C17 Ceramide is a synthetic ceramide that contains a non-natural C17:0 fatty acid acylated to sphingosine. It has been used as a marker of arylsulfatase A and sphingolipid activator B activity in patients undergoing enzyme replacement therapy for the genetic disease metachromatic leukodystrophy.

C18 D-threoCeramide (d18:1 18:0) is a synthetic ceramide and stereoisomer of C18 ceramide .1It inhibits rat brain mitochondrial ceramidase (mt-CDase) with an IC50value of 16.6 μM.2[Matreya, LLC. Catalog No. 1855] 1.Koolath, S., Murai, Y., Suga, Y., et al.Chiral combinatorial preparation and biological evaluation of unique ceramides for inhibition of sphingomyelin synthaseChirality32(3)308-313(2019) 2.Usta, J., El Bawab, S., Roddy, P., et al.Structural requirements of ceramide and sphingosine based inhibitors of mitochondrial ceramidaseBiochemistry40(32)9657-9668(2001)

C18 L-threo Ceramide is a synthetic ceramide and stereoisomer of C18 ceramide that has been used for structural characterization of natural sphingolipids. It inhibits rat brain mitochondrial ceramidase (mt-CDase) with an IC50 value of 0.21 mol% (16.8 μM).